title: Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC).
  
  
  METHODS
  Thirty-seven adult Japanese patients who had aHCC and liver cirrhosis were treated with combined intra-arterial 5-FU, cisplatin (CDDP), and leucovorin (LV). The Japan Integrated Staging score (JIS score) of each patient was 3 or more. The patients were divided into two groups, after which the 15 patients in group S were treated with 6-h infusion chemotherapy (LV at 12 mg/h, CDDP at 10 mg/h, and 5-FU at 250 mg/m2 per 4 h) and the 22 patients in group L were treated with 24-h infusion chemotherapy (LV at 12 mg/h, CDDP at 10 mg/h, and 5-FU at 250 mg/ m2 per 22 h). Continuous infusion chemotherapy was performed via the proper hepatic artery every 5 d for 4 wk using an implanted drug reservoir.
  
  
  RESULTS
  The percentages of patients with a partial response after 4 wk of chemotherapy were 6.7% in group S and 31.8% in group L. The survival of group L was significantly better than that of group S, with the median survival time being 496 d in group L and 226 d in group S (P < 0.05).
  
  
  CONCLUSIONS
  Continuous 24-h intra-arterial infusion is more effective for aHCC and can markedly prolong survival time as compared to 6-h infusion.
authors.affiliation: Division of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, Japan. hidenari@aol.com
authors.forename: Hidenari
authors.initials: H
authors.lastname: Nagai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kanayama
authors.forename: Katsuya
authors.initials: K
authors.lastname: Higami
authors.forename: Kouichi
authors.initials: K
authors.lastname: Momiyama
authors.forename: Akiko
authors.initials: A
authors.lastname: Ikoma
authors.forename: Naoki
authors.initials: N
authors.lastname: Okano
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Matsumaru
authors.forename: Manabu
authors.initials: M
authors.lastname: Watanabe
authors.forename: Koji
authors.initials: K
authors.lastname: Ishii
authors.forename: Yasukiyo
authors.initials: Y
authors.lastname: Sumino
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Miki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality*; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D007958:Leukocyte Count; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil